Design and testing for clinical trials faced with misclassified causes of death by Van Rompaye, Bart et al.
Design and testing for clinical trials faced with
misclassified causes-of-death
BART VAN ROMPAYE∗,1, SHABBAR JAFFAR2,
ELS GOETGHEBEUR1
1 Department of Applied Mathematics and Computer Science, Ghent University,
Krijgslaan 281, S9, 9000 Ghent, Belgium
2Department of Epidemiology and Population Health,
London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, U.K.
Abstract With clinical trials under pressure to produce more convincing re-
sults faster, we re-examine relative efficiencies for the semi-parametric comparison
of cause-specific rather than all-cause mortality events, observing that in many set-
tings misclassification of cause-of-failure is not negligible. By incorporating known
misclassification rates, we derive an adapted logrank test which optimizes power
when the alternative treatment effect is confined to the cause-specific hazard. We
derive sample size calculations for this test as well as for the corresponding all-cause
mortality and naive cause-specific logrank test which ignores the misclassification.
This may lead to new options at the design stage which we discuss. We re-examine
a recently closed vaccine trial in this light and find the sample size needed for the
new test to be 32% smaller than for the equivalent all-cause analysis, leading to a
reduction of 41,224 participants.
Cause-specific analysis; Clinical trials; Competing risks; Misclassification; Sample
size; Survival analysis; Verbal autopsy.
1 Introduction
Clinical trials with survival outcomes typically study products designed to
reduce the hazard of some targeted cause-specific event. For instance, tar-
geted cancer therapies aim to reduce the hazard of cancer-specific mortality
without affecting mortality from other causes (Cuzick, 2008). Vaccine tri-
als hope to reduce specific morbidity, but are not expected to prevent all
types of disease. In such case it is well known that a logrank comparison
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of all-cause mortality involves a diluted version of the cause-specific hazard
ratio and therefore loses power. The logrank test limited to cause-specific
events is then generally the preferred approach. In practice, the trade-off
between both tests needs to address feasibility and cost of cause assessment
as well as relative efficiency. This balancing act is part of standard design
considerations in any clinical trial with survival outcomes.
While efforts have been made to accommodate a proportion of missing
failure types in this setting (e.g. Rowe, 2006; Goetghebeur and Ryan, 1990;
Lu and Tsiatis, 2005) misclassification of causes-of-event is rarely acknowl-
edged. This happens frequently however, especially with verbal autopsies
used in developing countries (Soleman, Chandramohan and Shibuya, 2006)
and for events which are generally difficult or costly to diagnose (e.g. on-
set of Alzheimer’s disease, Waldemar and others 2007), but also when using
death registries or administrative databases in the study of common causes
of death in Western countries (e.g. Ladouceur and others , 2007). Uncertainty
on the cause-of-death may drain the power of a ’naive’ cause-specific anal-
ysis based on observed causes-of-death and confound estimators (as shown
in Anker, 1991; Maude and Ross, 1997). The absence of such effects in an
all-cause analysis may shift the balance of preference between both types
of analysis. Jaffar and others (2003) describe a vaccine trial where frequent
misclassification could lead to such severe loss of power that the primary end-
point would better be changed from acute lower respiratory tract infection
(ALRI)-specific mortality to all-cause mortality.
In this paper, we demonstrate how anticipated misclassification rates can
be incorporated in the analysis, thus deriving an adapted cause-specific lo-
grank test which recovers some of the power loss. To this end we model
proportional cause-specific hazards alternatives with possibly misclassified
observed failure patterns. A general test statistic is then derived from a par-
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tial likelihood involving weighted contributions from all observations. Under
simplifying assumptions this becomes an intuitive expression with weights
according to the failure type, an approach reminiscent of the one by Goetghe-
beur and Ryan (1990) for missing causes-of-death. This provides an efficient
alternative test to the current options for the intention-to-treat analysis. We
revisit the ALRI vaccine trial from this perspective and study how much
lower the needed sample size could have been for the adapted test.
In section 2 we motivate the problem in more detail. In section 3 we
define notation and the alternative hypothesis for which we seek better
power. We derive the adapted logrank test in section 4, sample size im-
plications are considered in section 5. Finally, we apply the new test statis-
tic to data from the Gambia Pneumococcal Vaccine Trial in section 6. Is-
sues of sensitivity and deviations from model assumptions are considered
in section 7. Selected details can be found in the supplementary materials
(http://www.biostatistics.oxfordjournals.org).
2 The Gambia Pneumococcal Vaccine Trial
Yearly more than one million children under the age of 5 die of acute respira-
tory infections caused by pneumococci (WHO, 1999). A large-scale random-
ized, double blind trial (the Gambia Pneumococcal Vaccine Trial) evaluated
the effectiveness of a pneumococcal conjugate vaccine in the developing coun-
try setting of eastern parts of The Gambia, where the rate of childhood ALRI
is up to tenfold higher than in industrialized countries (O’Dempsey and oth-
ers , 1996). Jaffar and others (1997) describe the mortality patterns in this
region. Final study results are published in Cutts and others (2005).
Initially the study focused on ALRI mortality, with cause-of-death (COD)
generally not determined clinically but through ’verbal autopsy’ or ’post-
mortem questionnaires’. Here, a team of three doctors assigns COD from
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data on the sequence and duration of the signs and symptoms preceding
death, gathered by retrospectively interviewing the deceased’s caretakers (De
Francisco and others , 1993). Even with two out of three doctors agreeing
on COD this method has low sensitivity for most CODs (sometimes below
50%, e.g. Snow and others 1992 on malaria and ALRI) and misclassification
is common. Prevalence of misclassification when using verbal autopsy is
reviewed in Anker (1991) or Maude and Ross (1997). An extensive review
of methods for verbal autopsy is found in Soleman and others (2006), while
Chandramohan and others (2005) formulate general concerns. In our work
we start from known misclassification probabilities.
Since the vaccine directly targets pneumococci little prevention of deaths
from causes other than ALRI is expected, even though the vaccine likely
prevents deaths from invasive pneumococcal diseases such as meningitis and
bacteraemia. Combined with high misclassification rates this could substan-
tially dilute the estimated treatment effect in a naive cause-specific analysis,
which thus loses power. As in Snow and others (1992), Jaffar and others
(2003) assume a sensitivity of 40% and specificity of 90% and show this
decreases the power in the Gambian setting from an expected 93% in the ab-
sence of misclassification to an expected 54%. The initial plan to examine the
vaccine impact on ALRI mortality thus changed focus to all-cause mortality.
However, the larger sample size requirement due to a diluted effect, combined
with the ethical desire to speed up trial completion, caused another change
in endpoint to disease-free survival with radiologically confirmed pneumonia
as endpoint (for results see Cutts and others 2005). Since misclassification
steered the primary endpoint away from a cause-specific interpretation, cor-
recting for it might bring back a viable cause-specific analysis.
Correcting for misclassification has happened for cause-specific mortality
fractions (Anker, 1991) and cause-specific mortality rates (Maude and Ross,
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1997). Archer and Ryan (1989) correct for misclassification in the cause-
of-death test for carcinogenicity using a missing data approach. Ebrahimi
(1996) adopted a fully parametric Bayesian approach to fit competing risk
models. Finally, Dewanji and Sengupta (2003) developed an EM-algorithm
to estimate cause-specific hazards non-parametrically when information is
missing at random but give no simple test of treatment effects. The MAR-
assumption does not allow for misclassification depending on the true cause-
of-death. They also introduce a Nelson-Aalen type estimator assuming one
always partially recognizes the true cause-of-death in the diagnosis, a setting
different from ours.
3 Notation and model assumptions





P (Di < t+ ∆t, δi = k|Di ≥ t;Zi)
where Di is the time to failure, δi = k is the true failure type which is 0
(other causes) or 1 (cause of interest) and Zi is a binary covariate, typically
a treatment: 0 for control and 1 for treatment with randomization probability
P (Zi = 1) = π. The null hypothesis of interest is h1(t; 1) = h1(t; 0), i.e. no
treatment effect on the type 1-specific hazard. Due to misclassification, as
indicated by Mi (1 if the failure type is misclassified and 0 otherwise), these
hazards cannot be observed directly. The observed failure type in the absence
of censoring is Fi = (δi −Mi)2.
We assume non-informative censoring can occur (meaning net and crude
cause-specific hazards coincide, Fleming and Harrington, 1991) in which case
Ci = 0 (and 1 otherwise). The observation time is denoted Ti, and for any
individual i we observe Ti, Ci, and Zi, and if Ci = 1 also Fi.
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As for missing data, some untestable assumption about the nature of the
errors is inevitable. We assume the misclassification probabilities are known
and may depend on failure time Di, true failure type δi and treatment Zi.
Assumption 1:
pr(Mi = 1|Di = ti, Ci = 1, δi = k, Zi = zi) = pk(ti; zi)
Such dependence on the true, unobserved failure type is often realistic. Fur-
ther expressions simplify substantially if these probabilities (then denoted
pk(t)) do not depend on Zi and we develop our results in those terms with-
out loss of generality. We call 1− p1(t) the sensitivity of the cause-of-death
diagnosis and 1− p0(t) the specificity.
We will seek to gain power targeting an alternative where Z has no in-






with hk(t) = hk(t; 0) the baseline hazard for a type k failure. While the
second equation is a standard proportional hazards assumption, the first
equation presents a stronger assumption that can be relaxed using a Cox-
type model, which is beyond the scope of this paper. Our method will have
optimal power under these assumptions, but is still valid for different true
alternatives.






As long as eξ(t) is arbitrary no restrictions are imposed on the different haz-
ards. However, for simplicity we will later choose a parametric shape, the




More flexible parametric forms are discussed in section 4 of the supplemen-
tary materials (http://www.biostatistics.oxfordjournals.org).
4 Derivation of the test statistic
Under assumptions 1-3, a partial likelihood is based on the conditional prob-
abilities of observing one of two event types at time ti: Fi = 0 or 1, given one
such event is observed in the risk set at ti. We first assume ξ(t) is known, for
example from a pilot study. With Ri the set of subjects who had not failed
or been censored just prior to failure time ti, the partial likelihood becomes:




h1(ti){e−ξ(ti)(1− p0(ti)) + eφzip1(ti)}∑





h1(ti){eφzi(1− p1(ti)) + e−ξ(ti)p0(ti)}∑
j∈Ri h1(ti){e
φzj(1− p1(ti)) + e−ξ(ti)p0(ti)}




wi{ti, Fi}(Zi − Z̄i) (4.1)
with Z̄i =
∑
j∈Ri Zj/ni the mean of the covariate values for the ni persons
at risk at ti and wi a weight function depending on the event time ti but also
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The second weight equals P (δi = 1|Fi = 1), the positive predictive value
of the diagnosis, the first weight is one minus the negative predictive value.
Hence, type 1 observations are downweighted since they might actually be
type 0 failures, while type 0 observations contribute to the statistic because
they could really be type 1 failures.
Through the martingale central limit theorem the standardized test statis-
tic U = T/ (V )1/2 can be shown to have an asymptotic standard normal












Dewanji (1992) proposed another partial likelihood for missing causes-
of-death, conditioning on any event type occurring (instead of the observed
type). This leads to a minor gain in power at the expense of an increased
complexity and a reduced robustness to model misspecification (Lu and Tsi-
atis 2005). We do not pursue this direction.
U depends on the relative cause-specific hazard e−ξ(t) through the weights
wi. If no a priori values are available for the ξ(ti) estimation is required, but
if a consistent estimator is used in (4.2) the asymptotic distribution of U
remains unchanged. While a nonparametric estimator based on a kernel-
weighted partial likelihood can be derived, one can also obtain simple consis-
tent estimators under parametric assumptions such as assumption 3’ (both
approaches are presented in the web-based supplementary material).
The remainder of this text assumes time-constant misclassification rates
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p0 and p1 and uses assumption 3’: ξ(t) = ξ. With Ok the total number of





This intuitive formula performs much better than the naive estimator O0/O1,
reducing to it when p0 = p1 = 0.
Under the same assumptions T and V become weighted sums of classical
logrank test contributions, enabling simple software implementation. For
the numerators Tk and denominators V
1/2
k of standard cause-specific logrank











When p0, p1 and ξ are time-constant we denote the weights in (4.2) wFi . In
the absence of misclassification wFi = Fi and U simplifies to the classical
cause-specific logrank statistic.
5 Sample size considerations
A main concern related to misclassification of the cause-of-death is how the
loss of power for a cause-specific analysis leads to an increase in the needed
sample size. Jaffar and others (2003) show for the pneumococcal vaccine trial
how a cause-specific analysis can become less attractive than the correspond-
ing all-cause analysis, prompting an (often undesirable) change of primary
endpoint. Since our test statistic accounts for misclassification rates some
power may be restored and the cause-specific analysis might be favoured from
an efficiency perspective when specific alternatives are targeted.
This section illustrates the possible impact of misclassification on the
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power and compares different possible tests at finite sample sizes by a simu-
lation study and asymptotically. An appropriate sample size formula for the
adapted test is derived.
5.1 Comparison of tests by simulation of the vaccine
trial setting
To examine the loss of power at various misclassification rates we imitate
the Gambian setting from Jaffar and others (2003), with 4 years of uniform
accrual into the clinical trial and 0.5 years of additional follow-up. In the
control group, the ALRI-specific death hazard h1 = 0.0059 and the hazard
of death from other causes h0 = 0.0275 (derived from Jaffar and others
1997). In the treatment group the ALRI-specific hazard is reduced by 31.5%
(φ = log(0.685) = −0.378). We further set π=0.5. For simplicity we use
constant hazards and administrative censoring only. We vary p1 from 0 to
60% and p0 from 0 to 20%, both in steps of 2%, covering the 60% and 10%
used by Jaffar and others (2003).
Sample size formula (5.1) is derived following Schoenfeld (1981) assum-
ing equal randomization probabilities (as in Schulgen and others 2005 or La-
touche and Porcher 2007). In the absence of misclassification W = 1 and we
obtain a conservative sample size of 22,760 needed to get 80% power using a
standard cause-specific logrank test at the 5% significance level.
Note that without treatment effect on the competing risk (assumption 2),
all components of expression (4.1) have theoretical expectation 0 under the
null, irrespective of the chosen weights. Hence, even under misspecification
of p0, p1 and ξ(t) the type I error rate is controlled. This was confirmed by
simulation for the different tests considered (supplementary materials).
We consider three cause-specific logrank tests. The infeasible classical
logrank test based on the true (in reality unobserved) failure type serves as
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Figure 1: Loss of power for the naive test as a function of the two misclas-
sification rates p0 and p1.
a reference and always yields a power of approximately 87% per design. For
the ’naive’ logrank test based on the observed (misclassified) failure types
the power is expected to decrease substantially as the misclassification prob-
abilities rise. The third test uses the adapted logrank statistic U = T/(V )1/2
derived in (4.1) and (4.3), with ξ estimated through (4.4). These tests are
called the reference, the naive and the adapted test, respectively.
Figure 1 gives the empirical power based on 1,000 simulations in function
of the misclassification probabilities for the naive test. The standard error
on the estimates is expected to be below 1%.
At the expected p0 = 10% and p1 = 60% the power drops from the
reference 87% to only 25%, an extreme loss which can in part be attributed
to the strong imbalance in mortality patterns (ξ << 0). The general features
for the adapted test (not shown) are the same but with a higher power at all
(p0, p1) combinations, leading to a power of 32% when (p0, p1) = (10%, 60%).
Although estimates for ξ from (4.4) can show extreme deviations under the
alternative, using the true ξ in the adapted test leads to little or no difference
in power. As table 1 will later show, the impact of using the adapted test
statistic grows as the imbalance in mortality patterns is less pronounced.
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The all-cause logrank test is unaffected by misclassification but has a
power of merely 23% due to the diluted treatment effect. Thus, even at
p0 = 10% and p1 = 60% the naive test has more power. Since the difference
is small one may still prefer the all-cause analysis however, if the exact p0
and p1 are unknown. In contrast, the adapted cause-specific analysis is a
more viable alternative since the difference with the all-cause logrank test is
more pronounced. Section 5.2 confirms this feature analytically.
5.2 Asymptotic relative efficiencies
Assuming ξ, p0 and p1 to be constant over time a more direct comparison of
the performance of the various tests is possible.





where super- and subscripts denote the observed failure type which deter-
mines the general weight factors w. Three special cases are:
1. the naive ’observed cause’-specific logrank statistic: w0 = 0, w1 = 1
2. the adapted logrank statistic: w0 = w0, w
1 = w1
3. the all-cause logrank test: w0 = 1, w1 = 1
In the adapted statistic the change from super- to subscript indicates going
from general weights to the weight factors wFi introduced at the end of
section 4.










Table 1: Asymptotic relative efficiencies for the three proposed tests.
naive adapted all-cause
naive 1







(where g(t) is continuous on [0, τ ] and the limit is achieved uniformly over
[0, τ ], the observation period) U is asymptotically normally distributed with
unit variance and mean µ. Under the alternative g(t) = 1 (a constant treat-
ment effect) the noncentrality parameter µ is:
φ∗ (w0p1 + w
1(1− p1))







as shown in the supplementary material (http://www.biostatistics.oxfordjournals.org).
Here si(t) is the limiting proportion of people at risk in treatment group i at
time t over the total number in the study n, and s(t) = s1(t) + s0(t).
By introducing the appropriate weights this leads to the asymptotic rel-





, which represent the ratios of
samples sizes asymptotically needed for two tests. The ARE’s, shown in
table 1, are determined by the relative strength of the competing causes and
the severity of the misclassification. Figure 2 shows the ARE’s as a function
of p0 and p1 for e
−ξ = 0.0059/0.0275.
When misclassification is rare the naive test is more efficient than an
all-cause analysis, but it loses efficiency quickly when p0 and p1 increase
(figure 2(b)). This illustrates that a cause-specific analysis is preferred over
a diluted all-cause analysis when the diagnosis is reliable.
The adapted cause-specific test is always at least as efficient as the naive
one since w0 and w1 are both positive and 0< p1 <1. Only when the sen-
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sitivity equals 1 the two tests are exactly the same (w0 = 0). Figure 2(a)
illustrates how with decreasing sensitivity the naive analysis loses efficiency
much faster than the adapted test because the estimated treatment effect
gets diluted, which is more pronounced for large p0. The impact of using the
adapted test depends on the mortality pattern through the ξ-dependence of
the weights w0 and w1. For example, with p0 small and p1 large (as in sec-
tion 5.1) the ARE becomes smaller with increasing e−ξ. In summary, the
adapted test always outperforms the naive one in the presence of misclassi-
fication, but this is modulated by various parameters in a complex way.
Finally, we are interested in the relative efficiency between the adapted
and the all-cause analysis. The efficiency of the adapted test is always equal
or higher to that of the all-cause analysis (figure 2(c)). Most is gained when
p0 and p1 are both extreme in the same direction (both high or both low).
At p0 = p1 = 50% the diagnosis is completely random and the two tests
are identical, yielding an ARE of 1. In fact, when p0 + p1 ≈ 1 the ARE
approximates 1, an effect modulated by ξ: the more positive ξ, the more
dominant the cause of interest, the smaller the dilution of the all-cause test
and the wider the p0, p1-surface at which the ARE approximates 1.
To summarize, an adapted cause-specific analysis is always more efficient
than an all-cause analysis, certainly making it an alternative to consider in
the design of a study.
(a) ARE(1,2) (b) ARE(1,3) (c) ARE(3,2)
Figure 2: Pitman ARE’s between the three candidate statistics, at ξ=
log(h1(t)/h0(t))= log(0.0059/0.0275) as in Jaffar and others (2003).
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5.3 Sample size formula
The loss of power with misclassification affects sample size calculations for
the cause-specific analysis. The noncentrality parameter for the adapted test
statistic (w0 = w0 and w





w0p1 + w1(1− p1)Q
where the integral expression Q involves the probability of seeing an event,
which is approximated using the event rate under the alternative in the
treated population. For constant hazards h0 and h1 a staggered accrual be-
tween time 0 and a and administrative censoring at time a+f (as in Schulgen
















where W = w0p1 +w1(1−p1). For interventions which lower the hazard, this
returns slightly conservative sample sizes recommended for design purposes.
The difference with standard expressions lies in the factor W 2 which is 1 in
the absence of misclassification. W thus allows to compare settings with and
without misclassification.
5.4 Sample size and ARE for the Gambian illustration
We illustrate the use of sample size formula (5.1) by returning to the set-
ting of Jaffar and others (2003): h1 = 0.0059, h0 = 0.0275, φ=log(0.685),
p0=10% and p1=60%. Under our assumptions the naive analysis requires a
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Figure 3: Comparison between empirical and theoretical power.
41% bigger sample size than our adapted analysis (ARE(2,1)=1.41). Since
ARE(3,1)=0.96 the naive analysis needs just a slightly smaller sample than
the all-cause analysis, so one may prefer the all-cause analysis when p0 and
p1 may be misspecified. However, ARE(3,2)=0.68 meaning the all-cause
test requires an approximately 50% larger sample than our adapted analysis,
making the adapted test appealing even under mild misspecification of p0
and p1. This is illustrated by a detailed sensitivity analysis in section 5 of
the supplementary material (http://www.biostatistics.oxfordjournals.org).
For the Gambian setting, figure 3 compares the empirical power for the
adapted test with the power from formula (5.1), based on 1000 simulations
at α = 5%.
At α = 5% and β = 20% the needed sample size for the adapted test
from (5.1) is 87,600. From the ARE this becomes 128,824 for the all-cause
analysis, yielding an impressive absolute difference of 41,224. The sample
size for the naive analysis is 123,516. Note that the decision to change the
endpoint from mortality to morbidity was based on these huge sample sizes.
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6 Application to data from the Gambia Pneu-
mococcal Vaccine Trial
The various analyses were applied to data from the Gambia Pneumococcal
Vaccine Trial (original results were published by Cutts and others , 2005). A
sample of 17,433 individuals consisted of children born between september
1999 and the beginning of the year 2003, of which 8,715 got vaccine and
8,718 placebo. The vaccination usually took place between 40 and 400 days
of age, with a median of 75 days. Follow-up stopped at the end of april 2004.
Further structure in the data is ignored for the purpose of illustration.
The data contained information on 491 deaths in the control and 426
in the treatment group. Of these 917 deaths, 186 were classified as due to
ALRI: 99 under control and 87 under treatment. The total follow-up time
was 18,601 person years in the control group and 18,640 person years in the
treatment group.
An all-cause logrank test for the treatment effect yields a p-value of 0.029,
for a naive ALRI-specific logrank test this becomes 0.371. Assuming p0 =
10% and p1 = 60% the estimate for e
−ξ = 1.92, which differs from the value
4.66 derived from Jaffar and others (1997). Of course, for the purpose of
testing our estimator was derived under the null which is rejected in this
example. Nevertheless, we find the competing risks to be more prevalent.
The adapted logrank statistic based on the estimated ξ is 1.921, yielding a
borderline significant p-value of 0.055.
The adapted cause-specific analysis gained substantial power compared
to a naive cause-specific analysis and yields a comparable (though slightly
higher) p-value than the all-cause analysis, despite the higher ARE. Reduced
power could come from model misspecification: Jaffar and others (2003) and
Cutts and others (2005) suspect the vaccine may also influence the hazards
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for some competing risks. This situation falls beyond the reach of our lo-
grank test and warrants further development into a Cox-type model, a topic
of ongoing research. As it stands, our current correction still appears a com-
petitive alternative for the all-cause comparison.
7 Discussion
This paper presents a test which corrects for known misclassification rates
when comparing cause-specific survival between treatment groups and recov-
ers power when treatment effect is confined to the disease-specific hazard. We
argued how the added power may at the design stage tip the balance between
choosing an all-cause versus cause-specific focus for the primary comparison.
When considering the trade off, it is important to recognize the specificity
of these two tests: the assumptions under which they typically operate and
the types of errors that can be made in either case, under the null and under
the alternative we anticipate here.
Standard group comparisons of all-cause hazards or of disease-specific
hazards are not concerned with how the treatment effect is distributed over
the different cause-specific hazards. For instance, equality between all-cause
hazards, the standard null hypothesis of the all-cause analysis, need not
imply strict equality between cause-specific hazards over the groups. Hence,
rejection of the cause-specific null need not imply rejection of the all-cause
null hypothesis and it could be argued that the cause-specific test is not
valid for an all-cause comparison since it compromises its type I error. While
technically correct, contrasting treatment effects on both competing hazards
would need to cancel each other out exactly at every time point in order
to produce identical all-cause hazards over time. The possibility of such
highly unlikely and unstable equilibrium point is easily ignored assuming
faithfulness as in causal inference (Spirtes and others , 1999).
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In the opposite direction, there is the risk of missing an effect on all-cause
mortality when performing a cause-specific analysis because the true effect
is not confined to the cause of interest as anticipated. As long as a study
is powered adequately to detect the partial effect on the cause of interest, it
will enjoy the benefit of added power in the presence of a synergistic effect on
the competing risk. In general, since design assumptions are not guaranteed
to hold, ethical considerations invariably warrant a complementing all-cause
analysis and verification of whether the observed effect on the cause of interest
is dampened, reversed or indeed emphasized by the effect on the competing
hazard. Recognizing the distinct effects on competing risks in the presence of
misclassified causes of death requires adapted cause-specific (Cox) regression
modelling which is the topic of further research.
Without claiming our adapted test is preferable in all situations, it de-
serves consideration in settings where the treatment effect is anticipated to
be primarily cause-specific on the grounds of a well protected type I error for
the null of no treatment effect on either hazard, combined with a possibly
substantial gain in power. Patients as well as the industry then stand to gain
from a speedier trial conclusion.
Under our assumptions, the adapted test is reliable when using diagnostic
tests with well-known sensitivity and specificity. The loss of power due to
absolute misspecification of the misclassification probabilities in the range of
10 to 20% is comparable to the conservativeness following from using (5.1).
This robustness allows one to base p0 and p1 estimates on literature data.
Alternatively one can estimate these probabilities from a representative di-
agnostic validation study. Even then, analyses can best be followed by a
sensitivity analysis using a predefined probable range for the misclassifica-
tion rates. Misspecification of the misclassification rates occurring at the
design stage can lead to both under- and overestimation of the power, but
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the power loss due to a misspecification of up to 20% will stay small in
certain settings. Prudence requires one considers the sensitivity issue seri-
ously when deciding on whether or not to use our method. Section 5 of the
web-based supplementary material presents an elaborate discussion of sen-
sitivity issues (http://www.biostatistics.oxfordjournals.org). Note that as a
rule, misclassification problems can be reduced by aggregating closely related
causes-of-death.
Even though the central quantities (4.1) and (4.3) do not rely on simpli-
fying assumptions regarding ξ(t), p0(t) and p1(t), the remainder of the text
does rely on them to make an adapted design more practical. In practice,
more freedom is possible at the analysis stage and one must balance bio-
logical relevance with analysis complexity to decide if and which simplifying
assumptions are useful. Piecewise constant models for anticipated varia-
tions in ξ, p0 and p1 imbed much more flexibility and retain the appealing
weighted logrank form. Details of such an approach are presented in the
supplementary materials, along with a nonparametric estimator for ξ(t) and
the incorporation of missing causes-of-death.
A referee has noted that modelling competing risks by means of the cu-
mulative incidence function (Fine and Gray, 1999) enjoys an increasing pop-
ularity. We agree it would be interesting to adapt the analog of the logrank
test in this setting in a way similar to ours.
While this article has focused on the testing problem, the methods pre-
sented can be further developed for estimation of effect sizes in a Cox-type
model with specific covariates acting on each of the considered cause-specific
hazards (similar to Goetghebeur and Ryan 1995). Obtaining the estimates
would however be more difficult and the method would best be supported by
software implementation to be practically useful.
In conclusion, we hope this adapted test and corresponding design offer
20
a cost-efficient alternative for some important classes of problems.
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